One major concern for producing therapeutic glycoprotein for human application in S.

cereviseae is that yeast N-glycosylation (50150 mannose residues per side chain) is of the
high mannose type, which confers a short half-life in vivo and hyperimmunogenicity and thus
render the therapeutic glycoprotein less effective.